
Eli Lilly and Company
LLYHealthcare|Drug Manufacturers - General|US
$1354.00
-10.73 (-0.79%)
DCF Value
$771.70
Tangible Book / Share
$13.81
Graham Number
$177.24
Cash / Share
$5.48
Next Earnings Report
Feb 3, 2027
EPS est. $11.20 · Revenue est. $24.58B
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest May 8, 2026 (424B2). Possible dilution.
Upcoming Data Readouts (42)
Dec 2026
Est. completion
Jan 2027
Est. completion
P1Diabetes Mellitus
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
NCT06982859n=95
Feb 2027
Est. completion
P1Obesity
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
NCT07476118n=150
Mar 2027
Est. completion
P2Severe Hypertriglyceridemia
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210n=60
Apr 2027
Est. completion
P1P2Carcinoma, Non-Small-Cell Lung
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640n=540
May 2027
Est. completion
Metastatic Breast Cancer
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
NCT06991946n=300
Jun 2027
Est. completion
P1Primary Myelofibrosis
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
NCT06343805n=256
Jul 2027
Est. completion
P2Recurrent Endometrial Carcinoma
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT04469764n=32
Jul 2027
Est. completion
Aug 2027
Est. completion
P3Obesity
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472n=600
Aug 2027
Est. completion
Aug 2027
Est. completion
P1Healthy Volunteers
A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)
NCT07801300n=204
Nov 2027
Est. completion
Nov 2027
Est. completion
P3Alzheimer Disease
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866n=2,996
Dec 2027
Est. completion
P3Crohn's Disease
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777n=90
Dec 2027
Est. completion
P3Obesity
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939n=150
Dec 2027
Est. completion
P1P2Relapsed/Refractory Chronic Lymphocytic Leukemia
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541n=194
Mar 2028
Est. completion
Mar 2028
Est. completion
P3Obesity
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886n=1,980
Mar 2028
Est. completion
P1Rheumatoid Arthritis (RA)
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
NCT07258849n=141
Awaiting Results (6)
Trials past primary completion date but still active — data readout may be imminent.
Aug 2026
P3
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722Jun 2026
P3
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06075667Jan 2026
P3
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359Jul 2023
P1
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001Recent Press Releases
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Nov 6, 2026 · PRNewsWire
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Nov 6, 2026 · Business Wire
Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
Nov 5, 2026 · PRNewsWire
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
Oct 29, 2026 · PRNewsWire
Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
Oct 28, 2026 · PRNewsWire
Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets
Oct 27, 2026 · PRNewsWire
Lilly declares fourth-quarter 2026 dividend
Oct 26, 2026 · PRNewsWire
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Oct 25, 2026 · PRNewsWire
SEC Filings (69)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Oct 29, 2026 | 8-K | Material event | DocumentIndex |
| Oct 19, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Oct 16, 2026 | SC 13D | Activist / 5%+ stake | DocumentIndex |
| Aug 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 5, 2026 | 8-K | Material event | DocumentIndex |
| Jul 30, 2026 | SC 13D | Activist / 5%+ stake | DocumentIndex |
| Jul 24, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jul 24, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Jul 23, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jun 23, 2026 | 11-K | DocumentIndex | |
| Jun 2, 2026 | 25-NSE | DocumentIndex | |
| May 20, 2026 | 8-K | Material event | DocumentIndex |
| May 11, 2026 | SD | DocumentIndex | |
| May 8, 2026 | 424B2 | Offering prospectus | DocumentIndex |
| May 7, 2026 | 8-K | Material event | DocumentIndex |
| May 6, 2026 | FWP | DocumentIndex | |
| May 6, 2026 | 424B2 | Offering prospectus | DocumentIndex |
| Apr 30, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Apr 30, 2026 | 8-K | Material event | DocumentIndex |
| Apr 29, 2026 | PX14A6G | DocumentIndex | |
| Apr 20, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 31, 2026 | DFAN14A | DocumentIndex | |
| Mar 26, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 20, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Mar 20, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 6, 2026 | PRE 14A | Proxy / shareholder vote | DocumentIndex |
| Feb 12, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 4, 2026 | 8-K | Material event | DocumentIndex |
| Jan 23, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jan 15, 2026 | SC 13D | Activist / 5%+ stake | DocumentIndex |
| Dec 9, 2025 | SC TO-T/A | Tender offer | DocumentIndex |
| Nov 21, 2025 | 8-K | Material event | DocumentIndex |
| Nov 7, 2025 | SC TO-T | Tender offer | DocumentIndex |
| Oct 30, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Oct 30, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Oct 30, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Oct 30, 2025 | 8-K | Material event | DocumentIndex |
| Oct 24, 2025 | SC TO-C | Tender offer | DocumentIndex |
| Oct 3, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |